(PINKSHEETS: AFAO), (PINKSHEETS: AECS), (OTCBB: DKAM).

Turning Pennies into dollars: (PINKSHEETS: AFAO), (PINKSHEETS: AECS), (OTCBB: DKAM).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://daat.realpennies.com

AFA Music Group, Ltd. (PINKSHEETS: AFAO)(March 13, 2008) announced yesterday that the release of the Sincere single is now supported by calls to radio. These calls keep a song in the minds of radio station music directors, who decide the daily play schedules for their stations. The objective of calling on the station is to get the Sincere single added to their play list. The personal touch of station calls significantly increases a records visibility.

Jon Goldwater, AFA CEO, remarks accordingly, "We have essentially staffed-up, teaming with an outside vendor to support the Sincere release with an intense radio calling campaign. The calling campaign follows the mail campaign that we executed a little over a week ago. We waited on calling so they could have a chance to listen to the single adequately. The station music directors that we have called so far are really embracing this single. The word is getting out about Sincere. The calls are verifying that. The calls are part of a broader marketing campaign that we have in store for Sincere. More as it develops over the next several weeks."

AFA Music Group signs recording artists for development. These assets can be entry level or established. AFA is acquiring publishing rights from its artists. AFA is collating these rights to develop an AFA music catalogue based on master recording ownership. AFA shares equity with its artists that includes recording royalties, CD sales, merchandise, sponsorship, touring, publishing, Internet downloads and ringtones.

For more info: http://daat.realpennies.com

AEC Holdings Corp. (PINKSHEETS: AECS)(March 13, 2008) announced earlier today that the Company's first family film will be based on the script, Scalawags, an original story co-written by Jon Van Dyke of AEC Holdings Corp. Scalawags is currently in pre-production.

Scalawags, a true family adventure story, is set on the coast and tells the tale of Miranda, a young girl sent to live with her eccentric Uncle Norville for the summer. One day, while playing in the old ship docked behind her uncle's house, Miranda uncovers a treasure map that not only provides adventure but could also help her uncle save his home and reputation. Miranda goes searching after the treasure to save her family while narrowly escaping capture.

"Scalawags is focused around our strengths -- working with animals and kids," says Jon Van Dyke, film director and Corporate Secretary of AEC Holdings Corp., "and will also allow us to showcase our vision for quality family-friendly entertainment."

About AEC Holdings Corp.

AEC Holdings Corp., through their subsidiary, Not By Sight Entertainment, is looking forward to working with Showcase Entertainment as a co-producer and world wide distribution agent. For more information, visit www.showcaseentertainment.com to see the quality of the product that they represent.

For more info: http://dkam.realpennies.com

Drinks Americas Holdings, Ltd. (OTCBB: DKAM) (the "Company")(March 13, 2008), a leading owner, developer and marketer of premium beverages, today announced earlier today the long awaited shipment and commencement of sales of its line of Trump Premium Flavored Vodkas, and the forward progress of orders for shipments of Trump Super Premium Vodka to Russia.

The line of Trump Premium Flavored Vodkas, crafted at the Wanders Distillery in Holland, is comprised of Trump Premium Citron, Grape, Orange, and Raspberry, distilled with all natural fruit flavors combined with the award-winning Trump Super Premium Vodka.

The Company has been accumulating orders for several months for thousands of cases of the flavored vodkas, but issues concerning selection of only the very best premium natural flavors had delayed production and shipment. Over 5,000 cases of Trump Premium Flavored Vodkas have been produced and will arrive next week for distribution in New York, New Jersey, Maryland, District of Colombia and Kentucky. Further orders are expected to be received when the product is unveiled at the upcoming Wine and Spirits Wholesalers Convention in Las Vegas in April.

J. Patrick Kenny, the CEO of the Company, said, "We have been anxiously awaiting the addition of Trump Premium Flavored Vodkas to our line of products. This will enhance and expand our shelf presence in bars and liquor stores, add revenue, and leverage the success we have had to date with award-winning Trump Super Premium Vodka. We are very happy with the great interest in this new line by retailers and our domestic and international distributors, and look forward to an accelerated rate of orders now that deliveries can be made." The Company also announced that it expects to ship several orders to Russia as the logistical issues that have caused recent delays in the shipment of Trump Super Premium Vodka to Russia have been resolved. Production pursuant to two orders for 4,000 cases each from Recolte, the Company's distributor in Russia, is now moving forward, with shipment pending the receipt of mandatory tax stamps from Russian import authorities. The Company highlighted the fact that its agreement with Recolte involves full payment for all goods in advance of shipping.

Patrick Kenny said, "As we work through our fourth fiscal quarter, we are encouraged to see the fruits of our intense labor. While shipments of our flavored vodkas and fulfillment of our projected orders from Russia were delayed last quarter, we now see that our work is on track to yield significant long term results. We are very satisfied and encouraged by the work done by Recolte in Russia to pre-sell Trump Super Premium Vodka, and are excited about the prospect of expanding our relationship with Recolte to include our upcoming cognac product with Dr. Dre. This anticipated cognac launch is to be the first of several projected products with Dr. Dre, and the Dr. Dre partnership is only the first transaction arising out of our partnership with Interscope Geffen A&M. It is no wonder that our board and our employees are extremely excited about our Company's prospects over the coming year."

About Drinks Americas

Drinks Americas develops, owns, markets, and nationally distributes alcoholic and non-alcoholic premium beverages associated with renowned icon celebrities. Drinks Americas' portfolio of premium alcoholic beverages includes Donald Trump's award winning Trump Super Premium Vodka and Willie Nelson's Old Whiskey River Bourbon. The Company's non-alcoholic brands include the distribution of Paul Newman's Own Lightly Sparkling Fruit Juice Drinks and Flavored Waters. Drinks Americas recently formed a joint venture with Universal Music's Interscope, Geffen, A&M Records to develop and market beverage products.

Other products owned and distributed by Drinks Americas include award-winning Damiana Liqueur and Aguila Tequila from Mexico, Cohete Rum Guarana from Panama, and Rheingold Beer. Damiana, Old Whiskey River, Aguila Tequila and Cohete Rum are Gold and Silver Medal award winners respectively from the International Beverage Tasting Institute and the San Francisco International Wine and Spirits Competition. For further information, please visit our website at www.drinksamericas.com.

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

Sponsored by: http://www.isthemarketopen.com

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com

(NASDAQ: PHRM), (PINKSHEETS: XYNG), (OTCBB: DKAM).

Turning Pennies into dollars: (NASDAQ: PHRM), (PINKSHEETS: XYNG), (OTCBB: DKAM).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://bdgw.realpennies.com

Pharmion (NASDAQ: PHRM) (February 11, 2008)MethylGene and Pharmion Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia

MethylGene Inc. (TSX: MYG) and Pharmion (NASDAQ: PHRM) announced earlier today that the European Medicines Agency (EMEA) and the European Commission (EC) designated MGCD0103, a histone deacetylase (HDAC) inhibitor, as an Orphan Medicinal Product for the treatment of acute myelogenous leukemia in the European Union (EU). Criteria for designation require that the product be intended for the treatment of life-threatening or serious conditions that are rare and affect not more than five in 10,000 persons in the EU.

Orphan Medicinal Product Designation allows special incentives for sponsors planning to test a product for use in a rare disease or condition generally characterized by a small number of patients. These incentives include eligibility for protocol assistance and possible exemptions or reductions of certain regulatory fees during development or at the time of application for marketing approval. Once approved, the product may qualify for 10 years of marketing exclusivity in the EU.

About MGCD0103

MGCD0103 is an orally-administered, isotype-selective HDAC inhibitor. The compound is currently in one Phase I combination clinical trial with Taxotere for solid tumors, two Phase I/II combination trials with Vidaza for hematological malignancies and with Gemzar for pancreatic cancer, and five Phase II clinical trials in hematological malignancies.

MGCD0103 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of Hodgkin lymphoma and has been designated an Orphan Medicinal Product by the EMEA for the treatment of Hodgkin lymphoma and acute myelogenous leukemia.

About Acute Myelogenous Leukemia (AML)

Acute myelogenous leukemia (AML) is a cancer of the blood and bone marrow that is characterized by the rapid proliferation (growth) of abnormal white blood cells. These cells are unable to perform their regular functions and eventually crowd out healthy red and white blood cells. Leukemia cells can also spread to other parts of the body. People afflicted with AML are susceptible to increased risk of infections, anemia and bleeding.

About 18,000 new cases of AML are diagnosed in Europe each year and the trend in overall incidence of AML has generally been stable or slowly increasing. AML is a rare form of cancer accounting for approximately 30 percent of all leukemias in the adult population and approximately 0.6 percent of all cancers. AML is estimated to affect less then two in 10,000 persons in the EU. The survival rate for AML at five years for adults under 55 is approximately 23 percent and for adults over 55 is approximately 10 percent.

Although several risk factors for AML have been identified, the specific cause of AML remains unclear. AML is a potentially curable disease; but only a minority of patients are cured with current therapies. Current treatments for AML include chemotherapy, blood transfusions and stem cell transplants.

About MethylGene

MethylGene Inc. (TSX: MYG) is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I and Phase II combination trials with Vidaza , Gemzar and Taxotere . MGCD265 is an oral kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. In addition, MethylGene's preclinical programs include: MGCD290 an HDAC inhibitor in combination with azoles for fungal infections and a sirtuins program for cancer. MethylGene's development and commercialization partners include Pharmion Corporation, Taiho Pharmaceutical and EnVivo Pharmaceuticals. Please visit our website at www.methylgene.com.

About Pharmion

Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza , a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at www.pharmion.com.

For more info: http://xyng.realpennies.com

Xynergy Corporation, Inc (PINKSHEETS: XYNG) (February 11, 2008) announced earlier today it intends to unveil its revolutionary Hydrogen Generator to key industry leaders, its shareholders, and to the media early this fall. The Company will announce sometime in the near future specific dates, locations and times relative to the demonstration of the prototype generator. The generator has been used to power a restaurant and has proven to power certain gas engines using water as the power source of the generator, including salt water. The company believes it will be able to mass produce their revolutionary generator cost efficiently, making it truly an alternative energy source. The company is working on prototyping several other revolutionary technologies and will be announcing the debuting of those as well. The generator will be marketed to restaurants, small offices and businesses, and residential homes initially.

This will be the first and only time anybody outside of management will have the opportunity to see this technology in operation. The Company intends on demonstrating several uses of its generator, including the powering of restaurants and other extraordinary uses. Production is underway.

Management has recently made several key announcements regarding the progress of the Company, including commencement of the filing process in order to become a fully reporting company pursuant to the Securities Exchange Act of 1934. Management has begun the registration process in order to facilitate management's intent to provide investors with greater ongoing disclosure and to move the trading of the Company's common stock from the current exchange to the Over The Counter Bulletin Board.

ABOUT XYNERGY CORPORATION

The company is engaged in the development and investment of alternative energy technology and the identification, marketing and utilization of applications for such technologies. The company has identified several business sectors that these technologies can serve, including restaurants, commercial bakeries, gas stations, and all small businesses, as well as gas engines for automobiles and boats. This technology has the potential to revolutionize the energy industry because it is believed that this technology, which uses water as a power source, is the only one in the world that can turn hydrogen into real power in a cost efficient manner, making it truly an alternative energy solution.

For more info: http://dkam.realpennies.com

Drinks Americas Holdings, Ltd. (OTCBB: DKAM)(February 11, 2008), a leading developer and marketer of premium beverages that partners with renowned icons, announced earlier today that it has made its second shipment consisting of 1,000 cases of Trump Super Premium Vodka to Russia. This shipment is part of Drinks Americas' contract with Recolte (its distribution partner in Russia) to purchase approximately $7.5 million of Trump Super Premium Vodka this year. This shipment, as well as others to Russia, are in coordination with Wanders, the Dutch distillery that produces Trump Super Premium Vodka. The 1,000-case shipment consists of various sizes of Trump Super Premium Vodka.

Recolte launched the Trump Super Premium Vodka brand at Moscow's Millionaires Fair in November 2007. The famous exhibition, held in one of Moscow's largest exhibition halls, featured the world's most prominent luxury goods and was attended by only qualified millionaires and Russia's most affluent consumers. In 2005, the vodka market in Russia was $10.2 billion and is expected to double in size by 2009.

Patrick Kenny, President and CEO stated, "We are happy that sales in Russia are underway and our partners have taken time to work through the logistical issues of starting to ship goods from our Dutch distiller to Russia. The sales revenue and profit margins from our expansion in Russia have significant implications for Drinks Americas' top and bottom line in the near term. The news of this expansion has interested other potential markets. We are looking aggressively at other export opportunities and expect to ship to partners in Asia this year."

ABOUT DRINKS AMERICAS

Drinks Americas develops, owns, markets, and nationally distributes alcoholic and non-alcoholic premium beverages associated with renowned icon celebrities. Drinks Americas' portfolio of premium alcoholic beverages includes Trump Super Premium Vodka and Willie Nelson's Old Whiskey River Bourbon. The Company's non-alcoholic brands include the distribution of Paul Newman's Own Lightly Sparkling Fruit Juice Drinks and Flavored Waters.

Other products owned and distributed by Drinks Americas include award-winning Damiana Liqueur and Aguila Tequila from Mexico, Cohete Rum Guarana from Panama, and Rheingold Beer. Damiana, Old Whiskey River, Aguila Tequila and Cohete Rum are Gold and Silver Medal award winners respectively from the International Beverage Tasting Institute and the San Francisco International Wine and Spirits Competition.

For further information, please visit our website at www.drinksamericas.com Drinks Americas was founded in 2004 by J. Patrick Kenny, a leading expert in beverage sales and marketing. Mr. Kenny developed his industry expertise in a variety of management positions at the world's leading beverage companies, including Joseph E. Seagram and Sons and The Coca-Cola Company. He has also acted as advisor to several Fortune 500 beverage marketing companies, and has participated in several beverage industry transactions.

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

Sponsored by: http://www.isthemarketopen.com

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com